Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
CDC42BPG Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CDC42BPG Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CDC42BPG sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CATSPERH Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CATSPERH Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CATSPERH sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CATSPER2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CATSPER2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CATSPER2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CATSPERE Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CATSPERE Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CATSPERE sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CATSPER3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CATSPER3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CATSPER3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CATSPER4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CATSPER4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CATSPER4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CAMKK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CAMKK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CAMKK2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CAMK1D Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CAMK1D Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CAMK1D sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CACNG8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CACNG8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CACNG8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CAMKK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CAMKK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CAMKK1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CATSPER1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CATSPER1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CATSPER1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CACNG7 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CACNG7 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CACNG7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →